Adrian Rawcliffe, CEO of Adaptimmune at EUBIO22 (Photographer: Rachel Kiki)
Adaptimmune trims pipeline, unveils plans to lay off 25%+ of employees amid sweetened ESMO data
Adaptimmune has a bitter pill to swallow after GSK axed its partnership in late October, coming in the form of a reorganization and budget cuts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
